Rejuvenating mitochondria and lysosomes to treat diseases
First-in-class molecules T-168 and T-621 reduce oxidative stress, inflammation and enhance autophagy
→ T-168 is ready for clinical phase 2 in neurodegenerative diseases (ALS, Parkinson’s, Alzheimer’s disease)
→ T-168 has been selected for the Neuro-SysMed Parkinson's disease SLEIPNIR trial with funding from Cure Parkinson’s, the Norwegian Parkinson’s Research Fund and the Norwegian Parkinson’s Association
→ T-621 is in IND enabling studies
Broad indication expansion opportunities in neurodegenerative, metabolic, muscle, and aging-related diseases
LEADERSHIP
Frederic Godderis, MS→ founder | ceo | director
Enchi Liu, PhD → co-founder | chief development officer
Andrew Lam, MS → co-founder | chief technology officer
Subhasis Roy, MBA → chief financial officer | business development
ADVISORS
Edgar Engleman, MD, PhD → scientific founder | prof. of Pathology and Medicine | Vivo Capital | Stanford University
Charalampos Tzoulis, MD, PhD → prof. of Neurology & Neurogenetics | University of Bergen, Norway
Sanjay Kakkar, MD → founder | director | ceo of Tensive SRL | Milan, Italy